LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held May 1-5 at the Washington State Convention Center. The presentation details are as follows:
-
Changes in intraocular pressure and conventional outflow
hydrodynamics following acute topical administration of trabodenoson
in living mice
Poster #: D0159
Authors: DS Albers, G Li, WK McVicar, and WD Stamer
Date: Wednesday, May 4, 2016
Time: 8:30 am to 10:15 am PDT
-
Tolerability and bioavailability of trabodenoson following local
dermal administration in minipigs
Poster #: B0239
Authors: WK McVicar, N Kim, and DS Albers
Date: Wednesday, May 4, 2016
Time: 11:00 am to 12:45 pm PDT
-
Safety and tolerability of trabodenoson in non-human primates
following 4 week ocular (topical) instillation
Poster #: A0104
Authors: CC Rich, DS Albers, R Guy, and WK McVicar
Date: Thursday, May 5, 2016
Time: 8:00 am to 9:45 am PDT
Inotek will have an exhibition booth set up at #1537.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s laboratories
and is designed to restore the eye’s natural pressure control mechanism.
Additionally, the Company is evaluating the potential for selective
adenosine mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit www.inotekpharma.com.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. These forward-looking statements often
include words such as “believe,” “expect,” “anticipate,” “intend,”
“plan,” “estimate,” “seek,” “will,” “may” or similar expressions.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
